Related references
Note: Only part of the references are listed.Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
G. L. Uy et al.
LEUKEMIA (2017)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Lars Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials (vol 31, pg 318, 2017)
G. Montalban-Bravo et al.
LEUKEMIA (2017)
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes
Stephan R. Bohl et al.
LEUKEMIA & LYMPHOMA (2017)
Therapy of older persons with acute myeloid leukaemia
Utz Krug et al.
LEUKEMIA RESEARCH (2017)
Decitabine in TP53-Mutated AML
Guillermo Montalban-Bravo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
Pin-Fang He et al.
ONCOTARGET (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy
Jan K. Hiller et al.
ANNALS OF HEMATOLOGY (2017)
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Bas J. Wouters et al.
BLOOD (2016)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
S. Jilg et al.
LEUKEMIA (2016)
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C. Coombs et al.
HAEMATOLOGICA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Koichi Takahashi et al.
ONCOTARGET (2016)
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Magnus Tobiasson et al.
ONCOTARGET (2016)
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
Seongseok Yun et al.
CLINICAL EPIGENETICS (2016)
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Jeannine Diesch et al.
CLINICAL EPIGENETICS (2016)
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C. Coombs et al.
HAEMATOLOGICA (2016)
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts
Tapan M. Kadia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
Azacitidine for the treatment of relapsed and refractory AML in older patients
Raphael Itzykson et al.
LEUKEMIA RESEARCH (2015)
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
Monica Cabrero et al.
LEUKEMIA RESEARCH (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis
Namyoung Jung et al.
NATURE COMMUNICATIONS (2015)
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Hyun Ae Jung et al.
ONCOTARGET (2015)
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
Thomas Cluzeau et al.
Oncotarget (2015)
Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
Sylvain Thepot et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
Bernard Tawfik et al.
ANNALS OF HEMATOLOGY (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Why methylation is not a marker predictive of response to hypomethylating agents
Maria Teresa Voso et al.
HAEMATOLOGICA (2014)
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Haiyang Yun et al.
HAEMATOLOGICA (2014)
Clinical development of demethylating agents in hematology
Shyamala C. Navada et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F. Traina et al.
LEUKEMIA (2014)
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A. Valencia et al.
LEUKEMIA (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
The mechanistic role of DNA methylation in myeloid leukemogenesis
J. Jasielec et al.
LEUKEMIA (2014)
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
Regina Garcia-Delgado et al.
LEUKEMIA RESEARCH (2014)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz et al.
CLINICAL CANCER RESEARCH (2013)
A Carrier-Mediated Prodrug Approach To Improve the Oral Absorption of Antileukemic Drug Decitabine
Youxi Zhang et al.
MOLECULAR PHARMACEUTICS (2013)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
A. Mims et al.
LEUKEMIA (2013)
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
E. H. Estey
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Concise Drug Review: Azacitidine and Decitabine
Ellen J. B. Derissen et al.
ONCOLOGIST (2013)
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Winston Timp et al.
NATURE REVIEWS CANCER (2013)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
Josephine Aimiuwu et al.
BLOOD (2012)
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
William Blum et al.
BLOOD (2012)
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
Pearlly Yan et al.
BLOOD (2012)
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
Thomas Prebet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation
Dong Yeok Shin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
S. Ettou et al.
LEUKEMIA (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
Richard L. Momparler
PHARMACEUTICALS (2012)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
3-Deazauridine enhances the antileukemic action of 5-aza-2 '-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase
Noel J. -M. Raynal et al.
LEUKEMIA RESEARCH (2011)
Increased methylation variation in epigenetic domains across cancer types
Kasper Daniel Hansen et al.
NATURE GENETICS (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Lanlan Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Paul W. Hollenbach et al.
PLOS ONE (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines
Taichun Qin et al.
BLOOD (2009)
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon et al.
BLOOD (2009)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Tamer E. Fandy et al.
BLOOD (2009)
Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities
Farhad Ravandi et al.
CANCER (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Amanda F. Cashen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
DNA methylation inhibitor 5-aza-2 '-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B
Stela S. Palii et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
C Stresemann et al.
CANCER RESEARCH (2006)
The Polycomb group protein EZH2 directly controls DNA methylation
E Viré et al.
NATURE (2006)
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal
K Ghoshal et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Nucleoside transporters in chronic lymphocytic leukaemia
M Pastor-Anglada et al.
LEUKEMIA (2004)
Membrane transporters and channels:: Role of the transportome in cancer chemosensitivity and chemoresistance
Y Huang et al.
CANCER RESEARCH (2004)
Share Paper
